Multicenter Open-label Observation Program in Patients With Chronic Hepatitis C and With Chronic Renal Failure (CRF) Receiving Peginterferon Alpha-2a (40 kDa) Pegasys
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.